As of Thursday close, T2 Biosystems Inc.’s (NASDAQ:TTOO) stock was up $0.02, moving up 9.92 percent to $0.23. The average number of shares traded per day over the past five days has been 2,607,880 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.1504 fall in that time frame. In the last twenty days, the average volume was 1,297,440, while in the previous 50 days, it was 1,174,938.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, TTOO stock retreated -51.55%. Shares of the company fell to $0.2110 on 05/12/22, the lowest level in the past month. A 52-week high of $1.48 was reached on 04/01/22 after having rallying from a 52-week low of $0.21. Since the beginning of this year, TTOO’s stock price has dropped by -54.48% or -$0.2812, and marked a new high 2 times. However, the stock has declined by -84.12% since its 52-week high.
T2 Biosystems Inc. (TTOO) last reported insider trading activity 35 days ago on Apr 08. Sprague John M, the Chief Financial Officer of the company, purchased of 10,000 shares for $0.48 on Apr 08. It resulted in a $4,767 investment by the insider. Giffin Brett A. added 10,600 shares at an average price of $0.49 on Apr 08. The insider now owns 10,600 shares following the transaction. On Apr 08, Chief Operations Officer Barclay Alec bought 12,952 shares at $0.50 apiece. The transaction was valued at $6,476.
In the three months ended September 29, T2 Biosystems Inc.’s quick ratio stood at 3.50, while its current ratio was 3.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 26.20% percent. Based on annual data, TTOO earned $7.36 million in gross profit and brought in $28.06 million in revenue.
In T2 Biosystems Inc.’s quarter-end financial report for September 29, it reported total debt of $47.79 million against cash and short-term investments of $10.0 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. TTOO’s revenue fell -11.6% to $7.43 million during the quarter, while net income inched up to $6.98 million. While analysts expected T2 Biosystems Inc. to report -$0.08 quarterly earnings, the actual figure was -$0.08 per share. During the quarter, the company generated -$9.69 million in EBITDA. The liabilities of T2 Biosystems Inc. were 73.44 million at the end of its most recent quarter ended September 29, and its total debt was $57.97 million. The value of shareholders’ equity is $171.04 million.
This quick technical analysis looks at T2 Biosystems Inc.’s (TTOO) price momentum. With a historical volatility rate of 167.80%, the RSI 9-day stood at 21.96% on 12 May.
With respect to its five-day moving average, the current T2 Biosystems Inc. price is down by -39.02% percent or -$0.1504. At present, TTOO shares trade -53.92% below its 20-day simple moving average and -57.27% percent below its 100-day simple moving average. However, the stock is currently trading approximately -42.40% below its SMA50 and -77.83% below its SMA200.
Stochastic coefficient K was 3.30% and Stochastic coefficient D was 2.75%, while ATR was 0.0419. Given the Stochastic reading of 9.64% for the 14-day period, the RSI (14) reading has been calculated as 26.57%. As of today, the MACD Oscillator reading stands at -0.0807, while the 14-day reading stands at -0.1103.
T2 Biosystems Inc. downgraded its rating on T2 Biosystems Inc. (NASDAQ: TTOO) to a Neutral in a note to investors on January 27, 2021. The analysts firm previously had a Buy rating on the stock.T2 Biosystems Inc. (TTOO) has been rated Buy by analysts. According to 0 brokerage firms, TTOO is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate T2 Biosystems Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $1.00, the current consensus forecast for the stock is $0.65 – $1.00. Based on these forecasts, analysts predict T2 Biosystems Inc. (TTOO) will achieve an average price target of $0.88.